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Introduction
The rise in antibiotic-resistant microorganisms in recent years has led to an increasing search for new antibiotics. Plant secondary metabolites have been used for centuries in traditional medicines and therefore represent a source of potentially active compounds [1] . Naturally occurring and synthetic quinoline derivatives have been studied for many years for their pharmacological activity, but only a few of these compounds have been developed for clinical use.
Mitscher et al. [2] found that the quaternary alkaloid pteleatinium chloride and the O-methylptelefolonium salt isolated from Ptelea trifoliata showed antimicrobial activity towards Staphylococcus aureus and Mycobacterium tuberculosis. A study by Fournet et al. [3] showed that the bioactivity of the plant Galipea longiflora against Leishmania amazonensis was due to 2-substituted quinoline alkaloids present in the plant, namely 2-propylquinoline and chimanine D.
Hanawa et al. [4] investigated the photo-activated antimicrobial activity of several furoquinoline derivatives such as skimmianine, kokusaginine, haplopine and flindersine against S. aureus. Towers et al. [5] carried out studies on the phototoxic effects of furoquinoline alkaloids. Five of the twelve compounds tested were active against Escherichia coli and Saccharomyces cerevisiae, namely isodictamnine, 7-desmethylskimmianine, maculosidine, maculine and dictamnine [5] . M a n u s c r i p t Skimmianine and kokusaginine have also shown good bioactivity against the fungus Leucoagaricus gongylophorus [6] .
Use of quinoline antimalarials such as quinine, chloroquine and amodiaquine in the treatment of malaria is well known. Many other synthetic quinoline derivatives have pharmaceutical significance. One group of synthetic quinolines that has significant use as antimicrobials in the treatment of many infections is the quinolones [7] . Nalidixic acid was the first of this group of compounds to be introduced and was used for the treatment of urinary tract infections in the 1960s. In the 1980s a succession of quinolone antimicrobials were introduced that differed from nalidixic acid by having a fluorine substituent in the 6-position and a piperazinyl derivative in the 7-position. These compounds are often referred to as fluoroquinolones. They are broad-spectrum antimicrobials and are used to treat sexually transmitted diseases and infections of the urinary tract, gastrointestinal tract, respiratory tract, skin, and bones and joints [8] .
This study reports the results of an investigation into the bioactivities of 60 quinoline derivatives against six different microorganisms by in-house microtitre assay. The minimum inhibitory concentration (MIC) of each quinoline derivative is reported. Quinolines that initially showed a low MIC against meticillin-resistant S. aureus (MRSA) and/or S. aureus were further tested against eight clinically isolated MRSA.
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Materials and methods

Quinolines
The quinoline derivatives investigated were available either from previous isolation from plant sources or from previous synthetic studies carried out in The University of Ulster, Coleraine, Northern Ireland [9-11]. Edulitine Tables 1-4 and their corresponding structures are illustrated in Figures 1-7 . All samples were dissolved in acetone and prepared at a concentration of 6.67 mg/mL.
Microtitre assay
The MIC values of the quinoline derivatives were estimated according to a previously reported microtitre method [13] . Lane 1 contained a blank, i.e. range for oxacillin started at 21.6 g/mL at Well 1 followed by serial dilution to 0.0105 g/mL at Well 12. The concentration of vancomycin and trimethoprim antibiotics started at 25 g/mL for Well 1 down to 0.0122 g/mL at Well 12. Lanes 4-8 contained the pure quinolines to be tested for antibacterial activity, which were made up in acetone from a stock solution of 6.67 mg/mL. To each well of these lanes, 25 L of sterile water was added, apart from the first two wells. In Well 1, 20 L of sterile water was added followed by 30 L of the test compound (final starting concentration in Well 1 was 1000 g/mL), which was then serially diluted down every second well to Well 11 of each lane. In Well 2, 30 L of sterile water was added followed by 20 L of the test compound (final starting concentration in Well 2 was 666 g/mL), which was serially diluted every second well down to Well 12. In this way, two concentration ranges were on the one plate with a starting concentration in Well 1 of 1000 g/mL and a final concentration of 20.8 g/mL in Well 12. The highly active compound 4-hydroxy-3-iodo-quinol-2-one (11) required a different concentration range starting at 100 g/mL in Well 1 followed by double dilution down each well to a final concentration of 0.049 g/mL in Well 12. All the microorganisms, which were grown overnight in MHB, were adjusted to 10 6 cells/mL before use, according to their optical density at 650 nm in MHB. 
Bacteria and antibiotics
The antimicrobial activities of the compounds were tested against the 
Results and discussion
The results are discussed under the different structural subgroups, comprising the quinol-2-ones, 3-C-dimethylallylquinol-2-ones, flindersine derivatives, quinoline dimers, dihydrofuroquinolines, linear and angular furoquinolines, and other quinolines. In this study, no bioactivity was defined as an MIC >1000 g/mL, mild bioactivity as an MIC in the range 501-1000 g/mL, moderate bioactivity as an MIC in the range 126-500 g/mL, good bioactivity as an MIC in the range 26-125 g/mL, strong bioactivity as an MIC in the range 10-25 g/mL and very strong bioactivity as an MIC <10 µg/mL.
Quinol-2-ones
The MICs of the 16 quinol-2-ones and the antibiotic controls are given in Table 1 with an MIC of 500 g/mL but was not active against the other microorganisms. When a methoxyl group was not present at the 7-position, as for 8-methoxy-4-hydroxy-quinol-2-one (6), the compound was no longer active against E. coli but showed mild activity against MRSA, S.
aureus and M. luteus. When the 4-hydroxy group in (6) was replaced with a methoxyl group or an ethoxyl group, there was no activity against the microorganisms, as seen with edulitine (7) Typhimurium and an MIC of 6.25 g/mL against S. aureus. Regarding these three compounds, it appears that iodine at position 3 and the absence of substitution in the benzene ring significantly enhances the bioactivity of these quinol-2-ones.
M a n u s c r i p t 4-Geranyloxy-quinol-2-one (13) had an MIC of 250 g/mL against MRSA and S. aureus and an MIC of 1000 g/mL against M. luteus. Quinol-2-ones with relatively long side chains in the 3-position, i.e. compounds (14), (15) and (16), did not show bioactivity.
3-C-dimethylallylquinol-2-ones
The MICs of the 3-C-dimethylallylquinol-2-ones are given in Table 2 Compound (26) was more bioactive than (17), possibly due to the presence of the 7,8-methylenedioxy group.
Flindersine derivatives
The MICs of the flindersine derivatives are given in Table 3 and moderate activity against S. aureus (MIC = 500 g/mL) and M. luteus (MIC = 250 g/mL).
Quinoline dimers
Compounds in this group (Fig. 4) showed no bioactivity against any of the microorganisms (Table 3 ).
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Dihydrofuroquinolines
The five dihydrofuroquinolines (Fig. 5 ) tested showed no bioactivity (Table   3 ).
Linear and angular furoquinolines
Ten linear and angular furoquinolines were investigated. Their MICs are given in Table 4 and their structures are presented in Fig. 6 . 5-Methylfuro- A c c e p t e d M a n u s c r i p t luteus (MIC = 1000 g/mL) and showed no activity against the other microorganisms. Thus, having a third methoxyl group in the 7-position appears to reduce the bioactivity of the molecule. 4-Methoxy-2-isopropylfuroquinoline (47) showed moderate activity towards MRSA and S. aureus and mild activity towards M. luteus. This also suggests that the presence of the isopropyl side chain increases bioactivity compared with (44).
Other quinolines
The MICs of the compounds in this group are shown in Table 4 showed moderate activity against MRSA (MIC = 500 g/mL), S. aureus (MIC = 333 g/mL) and M. luteus (MIC = 500 g/mL) and mild activity against B. subtilis (MIC = 1000 g/mL).
Bioactivity of selected quinolines against different strains of MRSA
Quinolines that showed an MIC of 125 g/mL against MRSA and/or S.
aureus were further tested against eight hospital isolates of MRSA. The results are shown in Table 5 . The microtitre assay for some of the M a n u s c r i p t compounds (10, 29, 30, 31 and 33) tested against IMRSA-1 is shown in 
Conclusions
Sixty quinolines grouped in seven structural subdivisions were investigated for their bioactivities against a number of microorganisms.
Thirty of the sixty quinolines showed bioactivity against the microorganisms investigated. The quinolines (26), (3), (10), (5), (43) and (11) showed activity against the Gram-negative bacterium E. coli.
Unfortunately, the activity of these compounds against the two Gramnegative bacteria only ranged from mild to moderate, with the exception of Of all the quinoline derivatives, 4-hydroxy-3-iodo-quinol-2-one (11) showed very strong activity, with MICs of 0.195 g/mL against S.
Typhimurium and E. coli, 0.39 g/mL against MRSA, M. luteus and B.
subtilis and 6.25 g/mL against S. aureus. When tested against eight clinical MRSA strains, (11) also showed strong to very strong bioactivity.
Against the majority of clinical isolates the MICs for (11) were equal to or lower than those for the antibiotic vancomycin used in the treatment of MRSA infections. The MIC against both EMRSA-15 and IMRSA-2 was 0.39 g/mL compared with 0.78 g/mL for vancomycin. Very strong activity was seen against IMRSA-1 (0.097 g/mL), DMRSA and NTMRSA (both MICs = 0.049 g/mL) compared with vancomycin with MICs ranging from 0.78 g/mL to 1.56 g/mL for the three hospital strains. Through further investigation into the mode of action of these quinolines and the testing of compounds of similar structure, in particular iodinated quinolines such as (11), it is possible that new therapeutic compounds active against MRSA could be discovered.
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M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t Fig. 1 . Structures of the quinol-2-ones. A c c e p t e d M a n u s c r i p t 1   Table 1 Minimum inhibitory concentrations (g/mL) of quinol-2-ones and the antibiotic controls (oxacillin, vancomycin and trimethoprim)
Quinol-2-one MRSA S. 4-Methoxy-1-methyl-quinol-2-one (2) >1000 >1000 >1000 >1000 >1000 >1000
1,3-Dimethyl-4-hydroxy-quinol-2-one (3) 1000 500 500 1000 1000 >1000
>1000 1000 >1000 >1000 >1000 >1000
7,8-Dimethoxy-4-hydroxy-quinol-2-one (5) >1000 >1000 >1000 >1000 500 >1000
8-Methoxy-4-hydroxy-quinol-2-one (6) 1000 1000 1000 >1000 >1000 >1000
Edulitine (7) [NS] a >1000 >1000 >1000 >1000 >1000 >1000
4-Ethyloxy-8-methoxy-quinol-2-one (8) >1000 >1000 >1000 >1000 >1000 >1000 4-Epoxygeranyloxy-quinol-2-one (12) >1000 >1000 >1000 >1000 >1000 >1000 M a n u s c r i p t >1000 >1000 >1000 >1000 >1000 >1000
4-Keto-3,3-di-(3'-methylbut-2-enyl)-quinol-2-one (15) >1000 >1000 >1000 >1000 >1000 >1000 A c c e p t e d M a n u s c r i p t 1 Table 2 Minimum inhibitory concentrations (g/mL) of 3-C-dimethylallylquinol-2-ones A c c e p t e d M a n u s c r i p t 1 7-Dimethylallyloxy-N-methylflindersine (34) 1000 500 250 >1000 >1000 >1000
Quinoline dimers
Quinolone dimer (35) >1000 >1000 >1000 >1000 >1000 >1000
Ketoquinoline dimer (36) >1000 >1000 >1000 >1000 >1000 >1000
Vepridimerine A (37) [NS] a >1000 >1000 >1000 >1000 >1000 >1000 Dihydrofuroquinolines M a n u s c r i p t M a n u s c r i p t 1 a >1000 >1000 1000 >1000 >1000 >1000
4-Methoxy-2-isopropyl-furoquinoline (47) 500 500 1000 >1000 >1000 >1000
Dehydroplatydesmine (48) >1000 500 >1000 >1000 >1000 >1000
Evoxine (49) [NS] a >1000 1000 >1000 >1000 >1000 >1000
Choisyine (50) [NS] a >1000 >1000 >1000 >1000 >1000 >1000
4-Chloro-6,7-methylenedioxy-furoquinoline (51) >1000 >1000 >1000 >1000 >1000 >1000
6,7-Methylenedioxyfuro-(2,3-b)-quinol-4-one (52) >1000 >1000 >1000 >1000 >1000 >1000
Other quinolines M a n u s c r i p t 2 2,4-Quinolinediol (53) >1000 1000 >1000 >1000 >1000 >1000
2,4-Dichloroquinoline (54) >1000 >1000 >1000 >1000 >1000 >1000
2,4-Dimethoxyquinoline (55) >1000 >1000 >1000 >1000 >1000 >1000
2,4,8-Trimethoxyquinoline (56) >1000 >1000 >1000 >1000 >1000 >1000
Orixine ( A c c e p t e d M a n u s c r i p t 1 M a n u s c r i p t 
